
|Articles|June 13, 2020
Flatiron Health’s Dr. Bobby Green Outlines Cancer Clinical Trial to Understand Genomic Changes in Tumors (pt. 3)
Author(s)Briana Contreras, Peter Wehrwein
Advertisement
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
2
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
3
Consolidative radiotherapy shows no survival benefit, added risk in SCLC
4
Anti-VEGF injection costs driven by missed work, travel vs drug costs | ASRS 2026
5



























